Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABBOTT ROLLING OUT LCx CHLAMYDIA TEST IN U.S. FOLLOWING 510(K) CLEARANCE; CORPORATE SALES HIT $10 BIL. IN 1995, UP 9.6%; HOSPITAL/LAB SALES GAIN 4.6%

This article was originally published in The Gray Sheet

Executive Summary

Abbott Laboratories is launching its LCx gene amplification test for chlamydia following receipt of 510(k) clearance from FDA on Dec. 8. The urine-based test is the first semi-automated gene amplification test to reach the U.S. market.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel